AVI Gets Patent For Ebola Drug

Xconomy Seattle — 

AVI Biopharma (NASDAQ: AVII), the Portland, OR-based developer of RNA interference drugs, said today it has gotten the second of two patents needed for its drug that treats infections with Ebola Zaire virus. The patents cover composition of matter and methods for treating Ebola with a range of compounds, and they expire Oct. 31, 2025, AVI said.